Prescription and over-the-counter medicine
Meclizine First approved as Antivert
Meclizine (Antivert) is a prescription and over-the-counter medicine with an FDA approval on record since 1957. FDA's NDC Directory lists it from 24 generic labelers, and pharmacies paid $0.0442 per meclizine 12.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the meclizine FDA label on DailyMed (effective June 2, 2025, Rising Pharma Holdings, Inc.); the NDA 10721 record on Drugs@FDA; every meclizine label on DailyMed.
Highlights of the record
FDA label of June 2, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMeclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
Forms and strengths
- 12.5 mg
- 25 mg
- 50 mg
Tablet; film-coated tablet; chewable tablet.
On the market
- Earliest approval on file
- February 14, 1957 Antivert, Casper Pharma Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 32 first March 19, 1975; 10 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 30 of which 24 under generic applications, 0 under brand applications, repackagers included; 49 more under the over-the-counter monograph, without an application
Supply and safety
- Pharmacy cost (NADAC)
- $0.0442 per tablet Meclizine 12.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 12 since 2015 1 Class I among all firms' recalls; latest March 16, 2026; 2 more by firms not listed as its makers
- FAERS reports
- 19,471 through July 30, 2026
What is meclizine used for?
From the label: indications and usageMeclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
Conditions named in the indications of meclizine's FDA labels, with every medicine labeled for each:
From other meclizine labelsNausea and vomiting: for the prevention and treatment of the nausea, vomiting, or dizziness associated with motion sickness
FDA pharmacologic class: Antiemetic.
Source: FDA drug label (Meclizine Hydrochloride), Rising Pharma Holdings, Inc., effective June 2, 2025 (SPL set c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd), via openFDA; the full label on DailyMed
Is there a generic for meclizine (Antivert)?
The FDA approved the first generic meclizine on March 19, 1975. 32 generic applications are approved; 10 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists meclizine from 24 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1957 earliest approval on file
- 1975 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for meclizine (Antivert)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0442 per Meclizine 12.5 mg tablet, down 11% from $0.0497 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Meclizine 12.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ft motion sickness 25 mg chwtb | Generic | $0.0333 per unit | n/a | -3% |
| Ft motion sickness 25 mg tablet | Generic | $0.128 per tablet | $3.84 | +0.1% |
| Gnp motion sickness 25 mg chwtb | Generic | $0.0333 per unit | n/a | -3% |
| Meclizine 12.5 mg caplet | Generic | $0.0313 per unit | n/a | -12% |
| Meclizine 12.5 mg tablet | Generic | $0.0442 per tablet | $1.33 | -11% |
| Meclizine 25 mg tablet | Generic | $0.0757 per tablet | $2.27 | -7% |
| Meclizine 25 mg tablet chewable | Generic | $0.0333 per tablet | $1.00 | -3% |
| Meclizine 50 mg tablet | Generic | $2.48 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $74.53 | -2% |
| Motion sickness rlf 25 mg tablet | Generic | $0.128 per tablet | $3.84 | +0.1% |
| Motion-time 25 mg tablet chewable | Generic | $0.0333 per tablet | $1.00 | -3% |
| Qc travel ease 25 mg chewable tablet | Generic | $0.0333 per tablet | $1.00 | -3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has meclizine been recalled?
The FDA's Enforcement Report lists 14 recalls naming meclizine since 2015: 1 Class I (the most serious), 5 Class II, 8 Class III; 2 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of meclizine and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 16, 2026 | Class II | Amerisource Health Services LLC | Failed tablet specifications. |
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
| March 8, 2022 | Class I | Jubilant Cadista Pharmaceuticals, Inc. | Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as … |
| September 2, 2021 | Class II | RISING PHARMACEUTICALS | Labeling: Incorrect Instructions |
| February 4, 2021 | Class II | Wilshire Pharmaceuticals Inc | Failed Dissolution Specifications |
| October 1, 2019 | Class III | Sato Pharmaceutical Inc. not a listed maker | Subpotent Drug |
| October 30, 2017 | Class III | Jubilant Cadista Pharmaceuticals, Inc. | Marketed without an approved NDA/ANDA: Bottles were released prior to final approval. |
| November 25, 2015 | Class III | Golden State Medical Supply Inc. | Failed Impurities/Degradation Specifications: Out of specification for impurities. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the meclizine label say about other medicines?
The meclizine label names no other medicine on this site. The labels of 1 other medicine name meclizine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Other labels that name meclizine
Source: FDA drug label (Meclizine Hydrochloride), Rising Pharma Holdings, Inc., effective June 2, 2025 (SPL set c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd), via openFDA; the full label on DailyMed
What do FAERS reports show for meclizine?
The FDA Adverse Event Reporting System holds 19,471 reports that list meclizine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,695 are coded as a death and 5,856 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as meclizine?
7 other medicines are given the same way (oral) and in the same FDA class as meclizine or labeled mainly for the same use (nausea and vomiting), the same class first. Nausea and vomiting lists all 16 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Trimethobenzamide | Nausea and vomiting | 4 labelers | n/a | No current entry |
| Ondansetron | Nausea and vomiting | 60 labelers | $0.0582 per tablet 4 mg tablet | No current entry |
| Prochlorperazine | Nausea and vomiting | 29 labelers | $0.162 per tablet 10 mg tablet | No current entry |
| Dimenhydrinate | Nausea and vomiting | none listed | $0.0575 per tablet 50 mg tablet | No current entry |
| Aprepitant | Nausea and vomiting | 5 labelers | $46.42 per capsule 40 mg capsule | A presentation being discontinued |
| Doxylamine and pyridoxine | Nausea and vomiting | 4 labelers | $1.09 per unit 10-10 mg | No current entry |
| Tradipitant | Nausea and vomiting | none listed | n/a | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does meclizine compare with medicines for the same use?
3 side-by-side pages set meclizine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to meclizine
- 7 medicines for the same use
- Other antiemetics
- the pharmacologic class, with prices and generics
- Meclizine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other